Thursday, September 28, 2023
March 28 - 30, 2020
ACC 2020
Universal CAR-T Therapy Produces CRs in Relapsed/Refractory T-ALL
ACC 2020
Radiation-Associated Childhood Cancer in Congenital Heart Disease
ACC 2020
AUGUSTUS: After ACS or PCI, Aspirin Gives AFib Patients Scant Benefit
ACC 2020
PCSK9 Inhibitors Unexpectedly Link With Lower VTE, Aortic Stenosis
ACC 2020
HFpEF: Gender Difference in Sacubitril/Valsartan Response Remains Mystery
ACC 2020
Low-Risk TAVR Loses Ground at 2 Years in PARTNER 3
ACC 2020
National Watchman Registry Reports Impressive Safety
ACC 2020
TWILIGHT-COMPLEX: Tap Ticagrelor Monotherapy Early After Complex PCI
ACC 2020
Sodium Nitrite Disappoints in Cardiac Arrest
ACC 2020
Edoxaban Noninferior to Warfarin After Valve Surgery?
ACC 2020
CIAO: Symptoms, Ischemia Don't Match in Puzzle That Is INOCA
ACC 2020
Radial Arteries Show CABG Survival Advantage Over Saphenous Veins
ACC 2020
Incremental Gains With Next-Gen MitraClip NTR/XTR: EXPAND
ACC 2020
Higher Protein Intake Linked to Lower Risk of AF
ACC 2020
VOYAGER PAD: Clopidogrel Adds No Benefit to Rivaroxaban+Aspirin
ACC 2020
PRECOMBAT at 10: Unusually Long-Term PCI vs CABG Data in LMCA
ACC 2020
REDUCE-IT: CV Benefit Directly Related to EPA Levels
ACC 2020
E3: A 'Glimmer of Hope' and Renewed Concerns Over E-Cigarettes
ACC 2020
ISCHEMIA Trials Land in NEJM While ACC.20 Airs Further Insights
ACC 2020
TWILIGHT Benefits of Dropping Aspirin Hold Up in Diabetes
ACC 2020
Alirocumab Effective in Homozygous FH
ACC 2020
Vein of Marshall Ethanol Infusion: A New Tool for AF Ablation
ACC 2020
New Lipid-lowering Drug Class Slashes LDL in HoFH Patients
ACC 2020
Outcomes-Based Measurement of TAVR Program Quality Goes Live
ACC 2020
Second Trial Supports Ticagrelor Alone in ACS After PCI: TICO
ACC 2020
Renal Denervation Shown Safe and Effective in Pivotal Trial
.jpg)
ACC 2020
Safe to Skip Post-TAVR Clopidogrel in Patients on OAC for AF
ACC 2020
CARAVAGGIO Expands DOAC Pool in Cancer-related VTE
ACC 2020
PRONOMOS: Rivaroxaban Bests Enoxaparin for VTE Prophylaxis
ACC 2020
Tepid Response to TAVR in Low-risk Patients With Bicuspid Valves
ACC 2020
UK TAVI: Similar Outcomes to Surgery in Real World
ACC 2020
Larger Absolute Rivaroxaban Benefit in Diabetes: COMPASS
ACC 2020
Primordial Cardiovascular Prevention Draws Closer
ACC 2020
Rivaroxaban Plus Aspirin Safely Benefits PAD Patients
ACC 2020
VICTORIA: Vericiguat Seen as Novel Success in High-Risk HFrEF
ACC 2020
More Than 1 in 3 Cardiologists Burned Out, Many Ready to Bolt
ACC 2020
Program Director Survey Shows Variation in CV Imaging Training
ACC 2020
TAILOR-PCI: Clopidogrel Genotyping Trial Narrowly Misses Endpoint
ACC 2020
Biomarkers in Young Adults May Predict Origins of HFpEF
ACC 2020
CTO PCI Linked to Worse Outcomes in Patients With Prior CABG
ACC 2020
The ACC.20/WCC Sessions Are Virtually Here: A Preview
ACC 2020
SPARCL: Atorvastatin Stroke Benefit Reinforced in New Analysis
ACC 2020
Dramatic Rise in Hypertension-Related Deaths in US
ACC 2020
Conscious Sedation During TAVR Best for Most Patients
ACC 2020
PARAGON-HF: Optimal Systolic Pressure in HFpEF is 120-129 mmHg
ACC 2020
TAVR Device Orientation May Reduce Coronary Overlap
ACC 2020
ACC Cancels Scientific Sessions Over Novel Coronavirus
© WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
VICTORIA PIs See Vericiguat as 'A Win' for High-Risk HFrEF
Heart Failure Highlights From the 2020 ACC Virtual Meeting
Cardiac Arrhythmia Highlights From ACC 2020
TAILOR-PCI and the Role of Genotype-Guided Antiplatelet Therapy
What Does VOYAGER PAD Mean for Antithrombotic Therapy?
What If There Is a Virtual ACC and Nobody Cares?
